Interview: Wendy Adams – General Manager, Galderma Canada
Wendy Adams, general manager of Galderma Canada, outlines the main achievements of the affiliate since 2013, the best practices she can share with Galderma globally when it comes to managing…
Galderma is a leading global pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. Galderma’s important investments in R&D, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, therapeutic skin care and aesthetic and corrective medical solutions) contribute to maintaining its strong leadership in dermatology. Galderma is committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 31 wholly-owned affiliates with a worldwide network of distributors and more than 4,000 employees.
Galderma Canada Inc. offers a product portfolio to treat a range of dermatological conditions including: acne, eczema, rosacea, psoriasis and non-melanoma skin cancer.
Strategic brands include:
Tactuo® and Differin® (acne), MetroGel® and Apprilon™ (rosacea), Clobex® (psoriasis), Metvix® (skin cancer), Cetaphil® (therapeutic skin care)
Wendy Adams, general manager of Galderma Canada, outlines the main achievements of the affiliate since 2013, the best practices she can share with Galderma globally when it comes to managing…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising…
Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to better tackle rare diseases in Canada. Especially in smaller provinces, it’s virtually impossible to predictably…
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied career at MSD in a wide variety of geographies. Canada’s…
Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to driving change at a much larger level via a ‘collective impact’ approach.…
A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial for companies hoping to succeed in the booming North American…
Canada is the only developed country with a universal healthcare system that does not provide universal coverage of prescription drugs. With a new national ‘pharmacare’ program being proposed to remedy…
Jan Hux, the president and CEO of Diabetes Canada calls for governments to place greater importance on partnerships with patient groups for the making of big decisions in healthcare. …
Durhane Wong-Rieger is the President & CEO of the Canadian Organization for Rare Disorders (CORD). In her first article for PharmaBoardroom, Durhane explains the changing landscape for access to rare…
Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in innovative biopharmaceutical companies in Canada. I’ve often wondered how things would be if…
As the healthcare industry continues to hype about AI’s potential to be transformative, it is important to remember that even software can harbour a certain amount of unconscious bias. Carla…
As the President of Innovative Medicines Canada, Pamela Fralick leads the industry association for Canada’s innovative pharmaceutical companies, working with its members and communities to ensure Canadians have access to…
See our Cookie Privacy Policy Here
